# Abemaciclib (LY2835219) Plus Fulvestrant Compared to Placebo Plus Fulvestrant in Previously Treated Breast Cancer

> **NCT05169567** · PHASE3 · ACTIVE_NOT_RECRUITING · sponsor: **Eli Lilly and Company** · enrollment: 368 (actual)

## Conditions studied

- Breast Neoplasm
- Neoplasm Metastasis

## Interventions

- **DRUG:** Abemaciclib
- **DRUG:** Fulvestrant
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT05169567
- **Lead sponsor:** Eli Lilly and Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2022-03-11
- **Primary completion:** 2024-02-08
- **Final completion:** 2027-12
- **Target enrollment:** 368 (ACTUAL)
- **Last updated:** 2026-01-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05169567

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05169567, "Abemaciclib (LY2835219) Plus Fulvestrant Compared to Placebo Plus Fulvestrant in Previously Treated Breast Cancer". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05169567. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*